Free Trial
NASDAQ:SYRS

Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

Syros Pharmaceuticals logo
$0.02 +0.02 (+1,143.75%)
As of 08/22/2025 03:18 PM Eastern

About Syros Pharmaceuticals Stock (NASDAQ:SYRS)

Key Stats

Today's Range
$0.0017
$0.0199
50-Day Range
$0.00
$0.03
52-Week Range
$0.00
$0.10
Volume
4,661 shs
Average Volume
186,243 shs
Market Capitalization
$533.96 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00
Consensus Rating
Hold

Company Overview

Syros Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

SYRS MarketRank™: 

Syros Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Syros Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Syros Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Syros Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Syros Pharmaceuticals are expected to decrease in the coming year, from ($2.94) to ($2.97) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Syros Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Syros Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Syros Pharmaceuticals has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Syros Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.31% of the float of Syros Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Syros Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Syros Pharmaceuticals has recently decreased by 32.26%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Syros Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Syros Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.31% of the float of Syros Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Syros Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Syros Pharmaceuticals has recently decreased by 32.26%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Syros Pharmaceuticals insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      12.26% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      91.47% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Syros Pharmaceuticals' insider trading history.
    Receive SYRS Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    SYRS Stock News Headlines

    Syros Pharmaceuticals trading resumes
    REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
    Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).tc pixel
    Syros Pharmaceuticals Plans to Wind Down Operations
    Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges
    See More Headlines

    SYRS Stock Analysis - Frequently Asked Questions

    Syros Pharmaceuticals' stock was trading at $0.2298 at the beginning of the year. Since then, SYRS stock has decreased by 91.3% and is now trading at $0.0199.

    Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) issued its quarterly earnings data on Thursday, October, 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08.
    Read the conference call transcript
    .

    Syros Pharmaceuticals shares reverse split on Monday, September 19th 2022.The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

    Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

    Syros Pharmaceuticals' top institutional investors include FNY Investment Advisers LLC. Insiders that own company stock include Jason Haas, Conley Chee, Timothy Tyson, David Roth, Richard A Young, Eric R Olson and Nancy A Simonian.
    View institutional ownership trends
    .

    Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Syros Pharmaceuticals investors own include Salesforce (CRM), QUALCOMM (QCOM), Bank of America (BAC), Bristol Myers Squibb (BMY), Pfizer (PFE), Twilio (TWLO) and AbbVie (ABBV).

    Company Calendar

    Last Earnings
    10/31/2024
    Today
    8/22/2025
    Next Earnings (Estimated)
    10/29/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:SYRS
    CIK
    1556263
    Fax
    N/A
    Employees
    120
    Year Founded
    2012

    Price Target and Rating

    High Price Target
    $1.00
    Low Price Target
    $1.00
    Potential Upside/Downside
    +4,925.1%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.00
    Research Coverage
    4 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($3.03)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$164.57 million
    Net Margins
    N/A
    Pretax Margin
    -25,275.20%
    Return on Equity
    -3,369.56%
    Return on Assets
    -97.04%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    2.25
    Quick Ratio
    2.25

    Sales & Book Value

    Annual Sales
    $386 thousand
    Price / Sales
    1.38
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $0.79 per share
    Price / Book
    0.03

    Miscellaneous

    Outstanding Shares
    26,832,000
    Free Float
    23,542,000
    Market Cap
    $533.96 thousand
    Optionable
    Optionable
    Beta
    1.31

    Social Links

    Analysts Agree—These Gold Picks Outshine the Rest Cover

    Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

    Get This Free Report

    This page (NASDAQ:SYRS) was last updated on 8/23/2025 by MarketBeat.com Staff
    From Our Partners